Adipose-derived allogeneic mesenchymal stem cell therapy (Steminent Biotherapeutics)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameAdipose-derived allogeneic mesenchymal stem cell therapy (Steminent Biotherapeutics)

Drug Alias NameMesenchymal stem cells - SteminentAllogeneic adipose-derived mesenchymal stem cells - Steminent BiotherapeuticsStemchymal

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsSpinocerebellar AtaxiasCerebellar AtaxiaAcute-On-Chronic Liver Failure +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesReprocell Inc Steminent Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesReprocell Inc Steminent Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSpinocerebellar Ataxias

Inactive IndicationsCerebellar AtaxiaAcute-On-Chronic Liver FailureLiver Failure, Acute

Other Information

ATC CodeN/A